Digest Network Come funziona
Network
/
Società
Ka
Non verificato

KaliVir Immunotherapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

8 comunicati stampa

Guarda tutti i comunicati
19/11/2025
Mercato del lavoro
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors
Fonte
KaliVir Immunotherapeutics, Inc.
Emittente
Business Wire
1.00
0
01/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
KaliVir Immunotherapeutics Announces Completion of First Intravenous Patient Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors
Fonte
KaliVir Immunotherapeutics, Inc.
Emittente
Business Wire
1.00
0
20/05/2025
Industria
Scienza
Biotecnologia
Oncologia
Salute
Igiene alimentare
Medicina - Varie
KaliVir Immunotherapeutics Announces Completion of First Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors
Fonte
KaliVir Immunotherapeutics, Inc.
Emittente
Business Wire
1.00
0
25/03/2025
Eventi
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting
Fonte
KaliVir Immunotherapeutics, Inc.
Emittente
Business Wire
1.00
0
18/11/2024
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Product Candidates
Fonte
KaliVir Immunotherapeutics, Inc.
Emittente
Business Wire
1.00
0
08/10/2024
Industria
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
KaliVir Immunotherapeutics Doses First Patient in Phase 1/1b Trial of VET3-TGI for Incurable, Advanced, Solid Tumors
Fonte
KaliVir Immunotherapeutics, Inc.
Emittente
Business Wire
1.00
0
04/09/2024
Biotecnologia
Farmaceutica
Salute
Oncologia
Mercato del lavoro
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
Fonte
KaliVir Immunotherapeutics, Inc.
Emittente
Business Wire
1.00
0
01/07/2024
Industria
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Oncolytic Immunotherapy VET3-TGI for Solid Tumors
Fonte
KaliVir Immunotherapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0